This module uses fundamental data of CAMP4 THERAPEUTICS to approximate the value of its Beneish M Score. CAMP4 THERAPEUTICS M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out CAMP4 THERAPEUTICS Piotroski F Score and CAMP4 THERAPEUTICS Altman Z Score analysis.
CAMP4
Beneish M Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Capex To Depreciation
Pb Ratio
Roic
Inventory Turnover
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Current Ratio
Receivables Turnover
Debt To Equity
Revenue Per Share
Debt To Assets
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Ev To Sales
Free Cash Flow Per Share
Days Of Inventory On Hand
Capex To Revenue
Cash Per Share
Days Payables Outstanding
Net Debt To E B I T D A
Tangible Book Value Per Share
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Graham Number
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Operating Cycle
Days Of Payables Outstanding
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Enterprise Value Multiple
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Good Will
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Common Stock
Common Stock Shares Outstanding
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Probability Of Bankruptcy
At this time, CAMP4 THERAPEUTICS's Debt To Assets are relatively stable compared to the past year. As of 03/21/2025, Interest Debt Per Share is likely to grow to 7.19, while Short Term Debt is likely to drop slightly above 602.8 K. At this time, CAMP4 THERAPEUTICS's EV To Operating Cash Flow is relatively stable compared to the past year. As of 03/21/2025, Current Ratio is likely to grow to 1.91, though Net Loss is likely to grow to (2.75).
At this time, it appears that CAMP4 THERAPEUTICS is a possible manipulator. The earnings manipulation may begin if CAMP4 THERAPEUTICS's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by CAMP4 THERAPEUTICS executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of CAMP4 THERAPEUTICS's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if CAMP4 THERAPEUTICS's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between CAMP4 THERAPEUTICS's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards CAMP4 THERAPEUTICS in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find CAMP4 THERAPEUTICS's degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as CAMP4 THERAPEUTICS. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CAMP4 THERAPEUTICS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CAMP4 THERAPEUTICS's managers, analysts, and investors.
Environmental
Governance
Social
About CAMP4 THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CAMP4 THERAPEUTICS PORATION's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CAMP4 THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CAMP4 THERAPEUTICS PORATION based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.